Instytut Msf Sp. z o.o.

Lodz 38 trials 15 recruiting

38 Registered trials

15 Currently recruiting

Organisation

Instytut Msf Sp. z o.o.

Location

Lodz, Poland

Identifier

ORG-100043985

Address

Ul. Pilota Stanislawa Wigury 19, 90-302, Poland

Departments

-
#048002: Instytut MSF Sp. z o.o.
#5701 Instytut Medyczny Santa Familia
Department of Oncology
Instytut Medyczny Santa Familia
Instytut MSF
Instytut MSF Sp. z o.o.
Klinika Onkologii
Medical Oncology
N/A
NA
Nie dotyczy
Oncology
Oncology Clinic
Oncology Department

Clinical trials at this site (38)

Search interface

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Ended

2022-501024-20-00 ER+/HER2- Early Breast Cancer 5 2023-07-25
Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects with Advanced KRASG12C Mut… Ended

2024-511548-19-00 Pancreatic Ductal Adenocarcinoma 1 2022-12-13
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Inoperable or Metastatic Hormone Receptor-positive, HER2-negative Breast Ca… Ended

2023-509631-37-00 "Inoperable or Metastatic Hormone Receptor-Positive, HE 5 2022-01-18
A randomized, double-blind, Phase III Study of AZD9833 plus CDK4/6 inhibitor in patients with metastatic breast cancer with detectable ESR1 … Ended

2023-503990-39-00 Estrogen Receptor-Positive, HER-2 negative Advanced Bre 5 2021-09-30
Study of AZD5305 as Monotherapy and with Anti-Cancer Agents in Patients with Advanced Solid Malignancies Ended

2022-502856-29-00 Advanced Solid Tumors 7 2021-07-27
Phase Ib/III Study of Capivasertib + CDK4/6 Inhibitors + Fulvestrant as Treatment for Advanced/Metastatic HR+/HER2-Breast Cancer (CAPItello-… Ended

2023-504997-39-00 Hormone Receptor-Positive and Human Epidermal Growth Fa 5 2021-06-14
A Randomised, Double-Blind, Phase III Study of AZD9833 plus Palbociclib versus Anastrozole plus Palbociclib in Patients with ER-Positive HER… Ended

2023-503995-26-00 Estrogen Receptor-Positive, HER2-Negative Advanced Brea 5 2021-05-11
PALLAS - PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy vers… Ended

2024-514841-12-00 To determine whether the addition of palbociclib to adj 5 2015-10-27
A trial to learn how well osimertinib (AZD9291) works to prevent cancer from coming back after surgery and how safe it is compared to the pl… Ended

2023-506524-82-00 Stage IB-IIIA non-small cell lung carcinoma, with a cen 5 2015-10-21
Study to test new drug eftilagimod alfa (also known as efti) combined with standard marketed treatments (pembrolizumab and chemotherapy) in … Ended

2024-513621-23-00 Advanced/metastatic non-small cell lung cancer (NSCLC) 5 2025-04-18
A Phase II trial find out the effectiveness and safety of durvalumab combined with olaparib compared to durvalumab alone, in treating patien… Ended

2024-512769-16-00 Stage IV Non Small Cell Lung Cancer whose tumors lack E 4 2018-11-14
Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer Ended

2024-515051-38-00 Non-small Cell Lung Cancer 5 2018-07-20
Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) Ended

2024-515052-20-00 Non-small Cell Lung Cancer 5 2017-09-20
Efficacy and safety of the proposed biosimilar PERT-IJS versus EU-Perjeta® along with trastuzumab and chemotherapy (carboplatin and docetaxe… Ended

2023-506163-34-00 Hormone Receptor Negative (HR-ve) Human Epidermal Growt 5